Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1NET 1Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Serotonin Syndrome 1Neuroendocrine Tumors 1Carcinoid Tumors, Intestinal 1Carcinoid Tumor 1

Interventions

lutetium Lu 177 dotatate 29Magnetic Resonance Spectroscopy 15Everolimus 10pembrolizumab 9Specimen Handling 9cabozantinib 7Nivolumab 7Lutetium-177 6surufatinib 5lenvatinib 5Octreotide 5Capecitabine 5177Lu-octreotide, DOTA(0)-Tyr(3)- 5olaparib 4lanreotide 4gallium Ga 68 dotatate 4amino-acid, glucose, and electrolyte solution 4X-Rays 4Lutetium 4Ipilimumab 4Injections 4Fluorodeoxyglucose F18 4copper dotatate CU-64 3atezolizumab 3Temozolomide 3Ga(III)-DOTATOC 3Cyclophosphamide 3Carboplatin 3pasireotide 2fludarabine phosphate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Random Allocation × NET × 1 year × Clear all
NCT05361668 2026-03-19

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Crinetics Pharmaceuticals Inc.

Phase 2 Completed
36 enrolled 19 charts
EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡